Covalent modification of cell surfaces with TLR agonists improves & directs immune stimulation

Chem Commun (Camb). 2013 Oct 25;49(83):9618-20. doi: 10.1039/c3cc45468a.

Abstract

We present a primary example of a cell surface modified with a synergistic combination of agonists to tune immune stimulation. A model cell line, Lewis Lung Carcinoma, was covalently modified with CpG-oligonucleotides and lipoteichoic acid, both Toll-like receptor (TLR) agonists. The immune-stimulating constructs provided greater stimulation of NF-κB in a model cell line and bone marrow-derived dendritic cells than the components unconjugated in solution.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Carcinoma, Lewis Lung / drug therapy*
  • Carcinoma, Lewis Lung / immunology
  • Cell Line, Tumor
  • Lipopolysaccharides / chemistry
  • Lipopolysaccharides / pharmacology*
  • NF-kappa B / immunology
  • Oligodeoxyribonucleotides / chemistry
  • Oligodeoxyribonucleotides / pharmacology*
  • Teichoic Acids / chemistry
  • Teichoic Acids / pharmacology*
  • Toll-Like Receptors / agonists*
  • Toll-Like Receptors / immunology

Substances

  • CPG-oligonucleotide
  • Lipopolysaccharides
  • NF-kappa B
  • Oligodeoxyribonucleotides
  • Teichoic Acids
  • Toll-Like Receptors
  • lipoteichoic acid